top
Search terms
Results 1 - 4 of 4 - ordered by :
Epeuropace

Death, severe stroke, acute heart failure, or severe limitations of exercise capacity in some patients contrast with frequent asymptomatic episodes of the arrhythmia in others.1113 Treatment options ...

Europace, AFNET, Paulus Kirchhof, Angelo Auricchio, Jeroen Bax, Harry Crijns, John Camm, Hans-Christoph Diener, Andreas Goette, Gerd Hindricks, Stefan Hohnloser, Lukas Kappenberger, Karl-Heinz Kuck, ...

Date : 01/11/2007 Item size : 664703 bytes
Ehjcardiovascrec

TGF-β is an important activator of chemokines and attracts monocytes into the heart.6 Micro-RNAs,7 plasminogen activator-inhibitor 1,8 or non-canonical, SMAD-independent activation of junction ...

Cardiovascular Research, Editorial, Larissa Fabritz, Paulus Kirchhof

Date : 01/09/2013 Item size : 186142 bytes
Epeuropace

Pharmaceutical companies are generally interested in this important group of patients and a relatively large number of antiarrhythmic agents are under development for several indications relating to ...

Europace, Review, Irina Savelieva, Paulus Kirchhof, Nicholas Danchin, Pieter A. de Graeff, A. John Camm

Date : 01/08/2011
Ehjournal

Abstract Catheter ablation is increasingly offered to patients who suffer from symptoms due to atrial fibrillation (AF), based on a growing body of evidence illustrating its efficacy compared with ...

European Heart Journal, Review, Paulus Kirchhof, Hugh Calkins

Date : 01/01/2017